[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Ozmosi [@OzmosiHealth](/creator/twitter/OzmosiHealth) on x 2627 followers Created: 2025-07-14 07:32:16 UTC $TAK, TYO:4502 Takeda reports positive outcomes from two Phase X trials of Oveporexton (TAK-861) in Type X Narcolepsy. More Info: $XBI $IBB $XPH $PPH  XXX engagements  **Related Topics** [$pph](/topic/$pph) [$xph](/topic/$xph) [$ibb](/topic/$ibb) [$xbi](/topic/$xbi) [more info](/topic/more-info) [$tak](/topic/$tak) [Post Link](https://x.com/OzmosiHealth/status/1944661207551811897)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Ozmosi @OzmosiHealth on x 2627 followers
Created: 2025-07-14 07:32:16 UTC
$TAK, TYO:4502 Takeda reports positive outcomes from two Phase X trials of Oveporexton (TAK-861) in Type X Narcolepsy.
More Info: $XBI $IBB $XPH $PPH
XXX engagements
/post/tweet::1944661207551811897